FANJ
REGN icon

Financial Architects (New Jersey)’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Architects (New Jersey)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-400
Closed -$4K – 1474
2016
Q1 		$4K Buy
+400
New +$165K ﹤0.01% 939

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Architects (New Jersey)'s REGN Position: Q3 2020 in Review

Financial Architects (New Jersey) sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 30 shares — an estimated $19K sold.

Financial Architects (New Jersey) first reported a position in REGN in Q3 2013 and held it in 16 quarters. The position peaked at $97K in Q2 2018. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

  • Financial Architects (New Jersey) reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 30 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $19K.
  • Financial Architects (New Jersey) first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 16 quarters.
  • Financial Architects (New Jersey)'s Regeneron Pharmaceuticals position peaked at $97K in Q2 2018.
  • 907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2020, filed 9 Nov 2020.